ArticleNature communications2023
Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 52 citations in OpenAlex.
- Early experience with cerebrospinal fluid cell-free DNA molecular profiling in a neuro-oncology practice.Journal of neuro-oncology · 2026Article
- Review
- Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Multiscale systems modelling of communication networks in brain metastasis.Experimental & molecular medicine · 2026Review
- Low-input CSF cfDNA shallow whole-genome sequencing for CNV-based diagnosis and monitoring of leptomeningeal metastasis in lung cancer.Acta neuropathologica communications · 2026Article
- Focused ultrasound for brain metastases.Neuro-oncology advances · 2026Review
- EGFR-TKI monotherapy versus combination therapy as first-line treatment for EGFR-mutant NSCLC with brain metastases: a real-world comparison analysis.BMC cancer · 2026Article
- Genetic and Immunohistochemical Profiling of Malignant Mesothelioma With Brain Metastasis: A Report of Two Cases.Cancer reports (Hoboken, N.J.) · 2026Article
- Brain metastasis from KRAS wild-type pancreatic cancer and organoid correlates: a case report.Journal of gastrointestinal oncology · 2026Article
- Revisiting nature of stage III non-small cell lung cancer: Anatomically defined, biologically systemic.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.Journal of translational medicine · 2026Review
- Integrated nomogram for predicting intracranial progression-free survival with EGFR-TKI combined with cranial radiotherapy: a multicenter study.European radiology · 2026Article
- Therapeutic advances with KRASCancer gene therapy · 2026Review
- Clinicopathological characteristics and prognosis of brain metastasis in non-small cell lung cancer: A retrospective study.Medicine · 2026Article
- The evolving landscape of brain metastasis: volume II.Trends in cancer · 2026Review
- Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.Theranostics · 2026Article
- Brain metastases from non-small cell lung cancer: molecular subtypes and emerging CNS-directed precision therapies.Frontiers in oncology · 2026Review
- Genomics correlates of brain metastasis and progression in colorectal cancer.Neuro-oncology · 2025Article
- Cellular dynamics in cerebrospinal fluid unveils the key regulators of intracranial response to immune checkpoint inhibitors in NSCLC brain metastases.Journal for immunotherapy of cancer · 2025Article
- Habitat Model Based on Lung CT for Predicting Brain Metastasis in Patients with Non-Small Cell Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
Up to 50% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), yet the study of BM genomics has been limited by tissue access, incomplete clinical data, and a lack of comparison with paired extracranial specimens. Here we report a cohort of 233 patients with resected and sequenced (MSK-IMPACT) NSCLC BM and comprehensive clinical data. With matched samples (47 primary tumor, 42 extracranial metastatic), we show CDKN2A/B deletions and cell cycle pathway alterations to be enriched in the BM samples. Meaningful clinico-genomic correlations are noted, namely EGFR alterations in leptomeningeal disease (LMD) and MYC amplifications in multifocal regional brain progression. Patients who developed early LMD frequently have had uncommon, multiple, and persistently detectable EGFR driver mutations. The distinct mutational patterns identified in BM specimens compared to other tissue sites suggest specific biologic underpinnings of intracranial progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.